UBS Maintains Neutral on Qiagen, Lowers Price Target to $47
UBS analyst Dan Leonard maintains Qiagen (NYSE:QGEN) with a Neutral and lowers the price target from $52 to $47.
Share
Why It Matters
A big bank's expert says Qiagen is okay but not exciting—and thinks its stock might be worth less money soon. This tells you the expert doesn't expect big surprises coming up, good or bad.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.